Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘hypertension research’ Category

Second paper about major blood pressure drug trial in Japan to be retracted

without comments

hr_cimageA second paper about a major randomized trial in Japanese patients with heart disease is being retracted, after an investigation reportedly found multiple problems with the paper.

As predicted by Pharma JapanHypertension Research is retracting a 2011 paper, already the subject of two errata. Although a spokesperson said she couldn’t say why the paper was being retracted, as the notice was still in production, editor Toshihiko Ishimitsu told us: Read the rest of this entry »

Raw files help fix 2003 figure by heart researcher accused of fraud

with 2 comments

7.cover

A researcher accused of misconduct by an anonymous Japanese blogger has corrected a 2003 paper in Circulation Research, after providing a university investigation with the original source files.

Allegations of fraud have dogged Shokei Kim-Mitsuyama for years, and even caused him to step down from his position as editor in chief at another journal. However, Kim-Mitsuyama and his colleagues call the latest correction a “mistake,” which didn’t affect any of the paper’s conclusions.

We’ve unearthed a total of five publications co-authored by Kim-Mitsuyama that have earned corrections, the latest of which cites an investigation by the university:

Read the rest of this entry »

Novartis Diovan scandal claims two more papers

with 6 comments

diabetes careA complicated story involving Novartis’s valsartan (Diovan) has led to the retraction of two more papers, one cascading from the other.

Last September, The Lancet retracted the Jikei Heart Study after a slew of retractions of related work prompted an investigation of valsartan research. That investigation found evidence of data manipulation and the failure of one researcher to note his Novartis affiliation. The company has apologized.

Here’s one retraction, from Diabetes Care, for “The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients With Type 2 Diabetes: The Shiga Microalbuminuria Reduction Trial (SMART):”

Read the rest of this entry »